glp 1 receptor agonists effects on cardiovascular risk reduction and Tolerability of GLP-1 Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Cardiovascular Effects of Glucagon-Like Peptide-1

Pharmacy benefit managers report that brand-name semaglutide medications currently cost approximately $200 to $400 per month in Canada, with the variation attributed to: Prescribed dosage strength Regional pharmacy markup policies Provincial drug pricing regulations Wholesale distribution agreements Generic Competition Timeline Impact The current pricing landscape comes as Health Canada continues reviewing nine generic semaglutide applications following the January 2026 patent expiration

Although diabetic patients and individuals with vascular disease face a higher baseline risk, anyone experiencing sudden changes in vision should seek immediate medical attention to protect their eye health and identify potential underlying conditions affecting the body

Ozempic arguably has the most name recognition, but it isnt the only GLP-1 agonist

While no clinical trials directly compare the medications, these two recent studies provide insights into common results

10.1016/S0167-0115(99)00089-0 [DOI] [PubMed] [Google Scholar] 90.Dworacka M, Krzyzagorska E, Iskakova S, Bekmukhambetov Y, Urazayev O, Dworacki G

In the meantime, we can use powerful tools to risk-stratify who attains access to these medications, starting with "sicker" patients